News from XBiotech A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Nov 04, 2014, 13:24 ET XBiotech Adds Daniel Vasella to its Board of Directors

 XBiotech announced today that Dr. Daniel Vasella has joined the Company as a member of the Board of Directors. Dr. Vasella was CEO of Sandoz...


Sep 11, 2014, 13:20 ET XBiotech Purchases Automated Vial Filling Machine, Prompting Increased Manufacturing Capabilities

XBiotech announced today it has taken delivery on its new high throughput filling machine that the Company says will be used to dramatically...


Sep 02, 2014, 14:08 ET XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer

 XBiotech announced today interim results from its fast-tracked Phase III study being conducted in the US for its anti-cancer agent...


Aug 01, 2014, 14:31 ET XBiotech Enrolls First Patient in Phase III European Registration Study Using Xilonix™ for Treatment of Colorectal Cancer

 XBiotech has enrolled the first patient into its European Phase III study using its novel cancer drug Xilonix™ for the treatment of...


Jun 23, 2014, 10:55 ET XBiotech Announces Addition of Vice President of Clinical Operations

XBiotech announced today that Gary Gonzales has joined the Company as Vice President of Clinical Operations. Mr. Gonzales will lead XBiotech's...


Jan 30, 2014, 10:50 ET XBiotech and European Medicines Agency (EMA) Agree on Phase III Registration Study for Treatment of Colorectal Cancer

 XBiotech announced today that its collaboration with the European Medicines Agency (EMA) has resulted in establishment of a regulatory path...


Jan 16, 2014, 15:28 ET XBiotech Announces Launch of Study to Treat Pyoderma Gangrenosum (PG)

 XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This...


Sep 18, 2013, 10:00 ET XBiotech Announces Collaboration with US Oncology Research in Pivotal Phase III Trial for Anti-Cancer Drug Xilonix™

 XBiotech, a privately held biotechnology company, announced today its collaboration with US Oncology Research to conduct a pivotal Phase III...


Sep 04, 2013, 10:50 ET XBiotech Announces it is Developing Therapy for MRSA

 XBiotech announced today that it has completed discovery and has begun pre-clinical development of a new True Human™ antibody therapy...


Aug 29, 2013, 15:29 ET XBiotech Announces Addition to its Board of Directors

 XBiotech announced today that Dr. Fabrizio Bonanni has joined the Company as a member of the Board of Directors. Dr. Bonanni joins XBiotech...


May 31, 2013, 10:00 ET XBiotech Announces Development of A Novel True Human™ Antibody Therapeutic

 XBiotech, a privately held biotechnology company, announced today its development of a novel True Human™ therapeutic antibody. The...


May 15, 2013, 14:15 ET XBiotech Announces Results for its XILONIX™ Treatment of Non-Small Cell Lung Cancer (NSCLC)

 XBiotech, a privately held biotechnology company, announced today its recent findings for Non-Small Cell Lung Cancer (NSCLC). Sixteen advanced...


May 01, 2013, 13:00 ET XBiotech to Present at UBS Global Healthcare Conference

XBiotech announced today that John Simard, Chairman, President & Chief Executive Officer, will present at the UBS Global Healthcare Conference...


Apr 24, 2013, 16:12 ET XBiotech Enrolls First Patient in Phase III Pivotal Trial of Xilonix™

XBiotech announced today enrollment of the first patient into its Phase III trial of Xilonix. The Pivotal study is designed to improve health and...


Mar 26, 2013, 12:10 ET XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK

 XBiotech, a privately held biotechnology company, announced the incorporation of its wholly owned Japanese subsidiary, XBiotech Japan KK. The...


Feb 26, 2013, 13:30 ET XBiotech Expands Portfolio to Include Biosimilars

XBiotech, a privately held biotechnology company, announced today that it is entering the biosimilar business. The Company is launching its...


Jan 03, 2013, 15:00 ET XBiotech Receives Fast Track Designation from FDA for True Human™ Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a for Restenosis

 XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation by the FDA for its...


Nov 20, 2012, 11:00 ET XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease

 XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study in patients...


Oct 29, 2012, 11:00 ET XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study

 XBiotech, a privately held biotechnology company, announced positive interim analysis results today from a Phase II study using a True Human...


Oct 17, 2012, 12:12 ET XBiotech Announces Progress in Clinical Development of Treatment for Psoriasis

XBiotech, a privately held biotechnology company, announced positive preliminary results today from their Phase II study using a True Human™...


Oct 03, 2012, 17:01 ET XBiotech Receives Fast Track Designation from FDA for Anti-Cachexia Drug Xilonix™

XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation for its anti-cachexia...